Biological specimen

ATCC Announces New Award from BARDA to Provide Centralized Storage and Bioprocessing Services for Project NextGen

Retrieved on: 
Thursday, January 4, 2024

ATCC will provide cold-chain and lifecycle management of biological specimens from Project NextGen clinical studies.

Key Points: 
  • ATCC will provide cold-chain and lifecycle management of biological specimens from Project NextGen clinical studies.
  • “Protecting the public’s health against multiple coronavirus variants with effective and longer lasting vaccines, as well as more resilient treatments, is critical.
  • By working together, we can help find innovative solutions to this challenge.”
    Under the Project NextGen initiative, ATCC will provide centralized and standardized services for receipt, processing, storage, protection, retrieval, packaging, shipping, tracking, and distribution of clinical specimens collected from participants across several clinical trials, including Phase IIb efficacy trials.
  • This further expands ATCC’s operation of BARDA’s Medical Countermeasures Clinical Studies Network ( CSN ) Biological Specimen and Investigational Product ( BSIP ) storage facility, which also provides centralized services, storage, and distribution of its clinical samples and investigational products across BARDA-supported studies.

DNAnexus and Discovery Life Sciences to Streamline Precision Health Data Analysis

Retrieved on: 
Wednesday, December 13, 2023

DNAnexus, Inc. , the provider of the Precision Health Data Cloud, and Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, today announced a collaboration to help streamline Discovery’s next-generation sequencing data analysis.

Key Points: 
  • DNAnexus, Inc. , the provider of the Precision Health Data Cloud, and Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, today announced a collaboration to help streamline Discovery’s next-generation sequencing data analysis.
  • As part of the agreement, Discovery will use the DNAnexus cloud and analysis tools to optimize analysis pipeline performance, mitigate risk, and accelerate project turnaround times.
  • The purpose-built DNAnexus Precision Health Data Cloud provides Discovery with a flexible compute, storage, and collaboration environment to access and analyze multimodal data.
  • “This collaboration is another validation of the power of our Precision Health Data Cloud to harness the full potential of large-scale multimodal data and unlock insights that improve patient care.”

Discovery Life Sciences Announces New CEO

Retrieved on: 
Tuesday, November 7, 2023

HUNTSVILLE, Ala., Nov. 7, 2023 /PRNewswire/ -- Discovery Life Sciences, the Biospecimen and Biomarker Specialists, announced today the appointment of Greg Herrema as its new chief executive officer. A leader with more than 20 years of experience across the life sciences and industrial sectors, Mr. Herrema will spearhead the next phase of Discovery's expansion. He succeeds Glenn Bilawsky, who announced his plans to step down after leading Discovery's transformation into a global provider of biospecimen products and multi-omic lab services.

Key Points: 
  • HUNTSVILLE, Ala., Nov. 7, 2023 /PRNewswire/ -- Discovery Life Sciences, the Biospecimen and Biomarker Specialists, announced today the appointment of Greg Herrema as its new chief executive officer.
  • A leader with more than 20 years of experience across the life sciences and industrial sectors, Mr. Herrema will spearhead the next phase of Discovery's expansion.
  • Mr. Herrema joins Discovery following a successful career at Thermo Fisher Scientific, where he served as senior vice president and president of the global life sciences company's $8 billion+ laboratory supply distribution business.
  • Greg Herrema, newly appointed CEO of Discovery, said:
    "I am thrilled to join the team at Discovery Life Sciences as CEO, and I'm honored to be part of a company at the forefront of advancing scientific research.

Discovery Life Sciences Announces New CEO

Retrieved on: 
Tuesday, November 7, 2023

HUNTSVILLE, Ala., Nov. 7, 2023 /PRNewswire/ -- Discovery Life Sciences, the Biospecimen and Biomarker Specialists, announced today the appointment of Greg Herrema as its new chief executive officer. A leader with more than 20 years of experience across the life sciences and industrial sectors, Mr. Herrema will spearhead the next phase of Discovery's expansion. He succeeds Glenn Bilawsky, who announced his plans to step down after leading Discovery's transformation into a global provider of biospecimen products and multi-omic lab services.

Key Points: 
  • HUNTSVILLE, Ala., Nov. 7, 2023 /PRNewswire/ -- Discovery Life Sciences, the Biospecimen and Biomarker Specialists, announced today the appointment of Greg Herrema as its new chief executive officer.
  • A leader with more than 20 years of experience across the life sciences and industrial sectors, Mr. Herrema will spearhead the next phase of Discovery's expansion.
  • Mr. Herrema joins Discovery following a successful career at Thermo Fisher Scientific, where he served as senior vice president and president of the global life sciences company's $8 billion+ laboratory supply distribution business.
  • Greg Herrema, newly appointed CEO of Discovery, said:
    "I am thrilled to join the team at Discovery Life Sciences as CEO, and I'm honored to be part of a company at the forefront of advancing scientific research.

Discovery Life Sciences Announces Major Strategic Expansions: New State-of-the-Art Facilities, Advanced Technologies, and Global Brand Enhancements

Retrieved on: 
Thursday, October 12, 2023

HUNTSVILLE, Ala., Oct. 12, 2023 /PRNewswire/ -- Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, has moved to its new global headquarters at the HudsonAlpha Institute of Biotechnology campus in Huntsville, Alabama.

Key Points: 
  • HUNTSVILLE, Ala., Oct. 12, 2023 /PRNewswire/ -- Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, has moved to its new global headquarters at the HudsonAlpha Institute of Biotechnology campus in Huntsville, Alabama.
  • Alongside this relocation, the company's AllCells cell and gene therapy division has set up its new divisional headquarters in Alameda, California.
  • In addition, Discovery is introducing Olink Explore HT proteomic services and debuting an all-new digital platform.
  • With support from the State of Alabama and HudsonAlpha, Discovery has opened its new 93,000-square-foot global headquarters building in Huntsville.

Discovery Life Sciences Announces Major Strategic Expansions: New State-of-the-Art Facilities, Advanced Technologies, and Global Brand Enhancements

Retrieved on: 
Thursday, October 12, 2023

HUNTSVILLE, Ala., Oct. 12, 2023 /PRNewswire/ -- Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, has moved to its new global headquarters at the HudsonAlpha Institute of Biotechnology campus in Huntsville, Alabama.

Key Points: 
  • HUNTSVILLE, Ala., Oct. 12, 2023 /PRNewswire/ -- Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, has moved to its new global headquarters at the HudsonAlpha Institute of Biotechnology campus in Huntsville, Alabama.
  • Alongside this relocation, the company's AllCells cell and gene therapy division has set up its new divisional headquarters in Alameda, California.
  • In addition, Discovery is introducing Olink Explore HT proteomic services and debuting an all-new digital platform.
  • With support from the State of Alabama and HudsonAlpha, Discovery has opened its new 93,000-square-foot global headquarters building in Huntsville.

Discovery Life Sciences expands high-throughput proteomics services

Retrieved on: 
Thursday, October 5, 2023

HUNTSVILLE, Ala., Oct. 5, 2023 /PRNewswire/ -- Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, today announced it has expanded its high-throughput proteomics services with the addition of Olink Explore HT. A next-generation proteomics solution, the new Olink Explore HT platform achieves greater precision and speed—enhancing Discovery's position as a comprehensive provider of proteomics and multi-omic services.

Key Points: 
  • HUNTSVILLE, Ala., Oct. 5, 2023 /PRNewswire/ -- Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, today announced it has expanded its high-throughput proteomics services with the addition of Olink Explore HT.
  • A next-generation proteomics solution, the new Olink Explore HT platform achieves greater precision and speed—enhancing Discovery's position as a comprehensive provider of proteomics and multi-omic services.
  • "We are extremely excited to see the entire portfolio of Olink proteomics solutions being adopted by Discovery Life Sciences, a global leader in proteomics applications," said Mike Irwin, Olink VP of Sales and Marketing.
  • "Discovery continues to stay ahead of the proteomics revolution," said Glenn Bilawsky, Discovery CEO.

Discovery Life Sciences expands high-throughput proteomics services

Retrieved on: 
Thursday, October 5, 2023

HUNTSVILLE, Ala., Oct. 5, 2023 /PRNewswire/ -- Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, today announced it has expanded its high-throughput proteomics services with the addition of Olink Explore HT. A next-generation proteomics solution, the new Olink Explore HT platform achieves greater precision and speed—enhancing Discovery's position as a comprehensive provider of proteomics and multi-omic services.

Key Points: 
  • HUNTSVILLE, Ala., Oct. 5, 2023 /PRNewswire/ -- Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, today announced it has expanded its high-throughput proteomics services with the addition of Olink Explore HT.
  • A next-generation proteomics solution, the new Olink Explore HT platform achieves greater precision and speed—enhancing Discovery's position as a comprehensive provider of proteomics and multi-omic services.
  • "We are extremely excited to see the entire portfolio of Olink proteomics solutions being adopted by Discovery Life Sciences, a global leader in proteomics applications," said Mike Irwin, Olink VP of Sales and Marketing.
  • "Discovery continues to stay ahead of the proteomics revolution," said Glenn Bilawsky, Discovery CEO.

DISCOVERY LIFE SCIENCES ACCELERATES CLINICAL TRIALS WITH ADDITION OF FULL-SPECTRUM CLINICAL FLOW CYTOMETRY

Retrieved on: 
Tuesday, July 11, 2023

HUNTSVILLE, Ala., July 11, 2023 /PRNewswire/ -- Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, announces the launch of state-of-the-art flow cytometry clinical trial services. Discovery has integrated Cytek Aurora instruments, which engage full-spectrum technology to deliver unprecedented flexibility to researchers, into one facility alongside its genomics, molecular pathology, and proteomics services―saving valuable time and further assuring high quality for drug and diagnostic development.

Key Points: 
  • Integrates state-of-the-art flow cytometry clinical trial services with leading genomics, proteomics, and molecular pathology solutions under one roof
    HUNTSVILLE, Ala., July 11, 2023 /PRNewswire/ -- Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, announces the launch of state-of-the-art flow cytometry clinical trial services.
  • Integrates clinical flow cytometry with leading genomics, proteomics, and molecular pathology services under one roof
    The addition of clinical flow cytometry strengthens Discovery's position as a leading specialty contract laboratory.
  • "We are excited to add the power of the newest Cytek Aurora instruments along with the scientific expertise in clinical flow cytometry services to our company," said Glenn Bilawsky, CEO of Discovery Life Sciences.
  • For more information about Discovery Life Sciences' innovative clinical flow cytometry services, please visit https://www.dls.com/biomarker-services/cell-services/flow-cytometry .

DISCOVERY LIFE SCIENCES ACCELERATES CLINICAL TRIALS WITH ADDITION OF FULL-SPECTRUM CLINICAL FLOW CYTOMETRY

Retrieved on: 
Tuesday, July 11, 2023

HUNTSVILLE, Ala., July 11, 2023 /PRNewswire/ -- Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, announces the launch of state-of-the-art flow cytometry clinical trial services. Discovery has integrated Cytek Aurora instruments, which engage full-spectrum technology to deliver unprecedented flexibility to researchers, into one facility alongside its genomics, molecular pathology, and proteomics services―saving valuable time and further assuring high quality for drug and diagnostic development.

Key Points: 
  • Integrates state-of-the-art flow cytometry clinical trial services with leading genomics, proteomics, and molecular pathology solutions under one roof
    HUNTSVILLE, Ala., July 11, 2023 /PRNewswire/ -- Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, announces the launch of state-of-the-art flow cytometry clinical trial services.
  • The addition of clinical flow cytometry strengthens Discovery's position as a leading specialty contract laboratory.
  • "We are excited to add the power of the newest Cytek Aurora instruments along with the scientific expertise in clinical flow cytometry services to our company," said Glenn Bilawsky, CEO of Discovery Life Sciences.
  • For more information about Discovery Life Sciences' innovative clinical flow cytometry services, please visit https://www.dls.com/biomarker-services/cell-services/flow-cytometry .